ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019
Combined Blockade of Activating
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
3.0field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 109 citations in OpenAlex.
- Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2023Trial
- Efficacy and Determinants of Response to HER Kinase Inhibition inCancer discovery · 2020Trial
- Bone Metastasis in Estrogen Receptor-Positive Breast Cancer: Molecular Insights and Therapeutic Advances.International journal of molecular sciences · 2026Review
- Endocrine therapy resistance of breast cancer: Important role of G protein-coupled estrogen receptor (GPER) and new therapeutic strategies.Genes & diseases · 2026Review
- Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer.Breast cancer (Tokyo, Japan) · 2025Review
- Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer.Biomolecules · 2025Review
- Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature.British journal of cancer · 2025Article
- Genomic landscape of hormone therapy-resistant HR-positive, HER2-negative breast cancer.Breast cancer research and treatment · 2025Article
- Genomic Predictive Biomarkers in Breast Cancer: TheInternational journal of molecular sciences · 2025Review
- Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer.Cancer discovery · 2025Article
- Molecular classification of hormone receptor-positive /HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies.Signal transduction and targeted therapy · 2025Article
- Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer.Breast (Edinburgh, Scotland) · 2025Review
- Neoadjuvant HER2 inhibition induces ESR1 DNA methylation alterations resulting in clinically relevant ER expression changes in breast cancers.Cancer communications (London, England) · 2025Article
- Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer.International journal of molecular sciences · 2025Article
- Computational-aided rational mutation design of pertuzumab to overcome active HER2 mutation S310F through antibody-drug conjugates.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- HER2-Positive Breast Cancer Treatment and Resistance.Advances in experimental medicine and biology · 2025Review
- Survival outcomes for HER2-low breast cancer: Danish national data.Acta oncologica (Stockholm, Sweden) · 2024Article
- Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer.Molecular oncology · 2024Article
- ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity.Virchows Archiv : an international journal of pathology · 2024Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 1 country.
Sarah CroessmannDepartment of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Luigi FormisanoDepartment of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Lisa N KinchHoward Hughes Medical Institute, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0003-3041-2615
Paula I Gonzalez-EricssonBreast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-6292-6963
Dhivya R SudhanDepartment of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Rebecca J NagyGuardant Health, Inc., Redwood, California.
Aju MathewUniversity of Kentucky Markey Cancer Center, Lexington, Kentucky.
Eric H BernickerHouston Methodist Cancer Center, Houston, Texas.ORCID 0000-0002-0829-2111
Massimo CristofanilliLurie Comprehensive Cancer Center, Chicago, Illinois.
Jie HeFoundation Medicine, Inc., Cambridge, Massachusetts.
Richard E CutlerPuma Biotechnology, Inc., Los Angeles, California.
Alshad S LalaniPuma Biotechnology, Inc., Los Angeles, California.
Vincent A MillerFoundation Medicine, Inc., Cambridge, Massachusetts.
Richard B LanmanGuardant Health, Inc., Redwood, California.ORCID 0000-0001-8122-4329
Nick V GrishinHoward Hughes Medical Institute, UT Southwestern Medical Center, Dallas, Texas.
Carlos L ArteagaDepartment of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. carlos.arteaga@utsouthwestern.edu.
Vanderbilt University Medical Center · USSouthwestern Medical Center · USGlobalFoundries (United States) · USGuardant (United States) · USPuma Biotechnology (United States) · USCancer Care Specialists of Illinois · USHouston Methodist · USMarkey Cancer Center · US
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MUT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7MTISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7MComputational methods for structural-functional studies of proteinsR01GM094575 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI GRISHIN, NICK V. · 2010 to 2017
$2.4MComputational analysis of proteinsR35GM127390 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI GRISHIN, NICK V. · 2018 to 2022
$1.5MHoward Hughes Medical InstituteNCI NIH HHS P30 CA068485NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA098131NIGMS NIH HHS R01 GM094575NIGMS NIH HHS R35 GM127390
Abstract
purposeWe examined the role of EXPERIMENTAL
design
resultsGenomic data revealed a higher rate of
conclusions
Indexed as
AnimalsBreast NeoplasmsDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphaEstrogensFemaleFulvestrantGene Expression Regulation, NeoplasticHeterograftsHumansMCF-7 CellsMechanistic Target of Rapamycin Complex 1MiceMutationPhosphatidylinositol 3-KinasesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesERBB3 protein, humanESR1 protein, humanEstrogen Receptor alphaEstrogensFulvestrantMechanistic Target of Rapamycin Complex 1neratinibPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsQuinolinesReceptor, ErbB-3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.